Salivary 1,5-Anhydroglucitol and its Correlation with Postprandial Hyperglycemia: Development and Validation of a Novel Assay
- PMID: 37266531
- PMCID: PMC10230528
- DOI: 10.4103/ijabmr.ijabmr_378_22
Salivary 1,5-Anhydroglucitol and its Correlation with Postprandial Hyperglycemia: Development and Validation of a Novel Assay
Abstract
Background: Saliva has the potential to be used as a noninvasive sample for testing hyperglycemia in diabetes mellitus. Serum 1,5-anhydroglucitol (1,5-AG) decreases with an increase in blood sugar >180 mg/dl. We hypothesized that salivary 1,5-AG can be used to identify blood sugar higher than 180 mg/dl using a novel biochemical method.
Aim: This study aimed to develop a novel biochemical method for serum and salivary assessment of 1,5-AG and assess its correlation with postprandial blood sugar (PPBS) >180 mg/dl.
Methodology: The study comprised 45 controls (healthy individuals) and 45 cases (type 2 diabetic patients with PPBS >180 mg/dl). Blood and salivary samples were collected according to the study protocol. A new method was developed for the quantification of 1,5-AG in serum and saliva using liquid chromatography-mass spectrometry.
Results: The value of serum (mean -22.19 μg/ml and median -22.12 μg/ml) and salivary (mean -0.124 μg/ml and median -0.088 μg/ml) 1,5-AG was higher in healthy individuals compared to corresponding serum (mean -3.89 μg/ml and median -2.52 μg/ml) and salivary (mean -0.025 μg/ml and median - 0.025 μg/ml) levels in diabetics with PPBS >180 mg/dl. In diabetics, a significant negative correlation was noticed with PPBS levels and 1,5-AG levels in serum and saliva. Salivary 1,5-AG level <0.054 μg/ml had an 86.4% sensitivity and 87.2% specificity in predicting a blood sugar value >180 mg/dl.
Conclusion: The results of our study suggest that the short-term glycemic marker 1,5-AG can be detected in saliva and can be useful as an adjunct marker in monitoring of glycemic status in diabetic patients.
Keywords: Liquid chromatography–mass spectrometry; salivary 1,5-anhydroglucitol; salivary biomarker; short-term glycemic marker; tandem mass spectrometry; type II diabetes mellitus.
Copyright: © 2023 International Journal of Applied and Basic Medical Research.
Conflict of interest statement
There are no conflicts of interest.
Figures




References
-
- Kaufman E, Lamster IB. The diagnostic applications of saliva –A review. Crit Rev Oral Biol Med. 2002;13:197–212. - PubMed
-
- Pink R, Simek J, Vondrakova J, Faber E, Michl P, Pazdera J, et al. Saliva as a diagnostic medium. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009;153:103–10. - PubMed
-
- Armbruster DA. Fructosamine:Structure, analysis, and clinical usefulness. Clin Chem. 1987;33:2153–63. - PubMed
-
- Wright LA, Hirsch IB. The challenge of the use of glycemic biomarkers in diabetes:Reflecting on hemoglobin A1C, 1,5-anhydroglucitol, and the glycated proteins fructosamine and glycated albumin. Diabetes Spectr. 2012;25:141–8.
-
- Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006;29:1214–9. - PubMed
LinkOut - more resources
Full Text Sources